Celltrion Usa Signs Express Scripts Deal: Fda-approved Zymfentra

By Author: Ben Gross
Total Articles: 444
Comment this article

Celltrion USA has recently announced a new agreement with Express Scripts, a prominent pharmacy benefit manager (PBM) that represents health plans for over 100 million individuals. Starting from April 4, 2024, this agreement will provide preferred brand access to ZYMFENTRA on the Express Scripts National Preferred Formulary, benefiting 21.9 million insured lives. With this agreement, Express Scripts can now include ZYMFENTRA™ (infliximab-dyyb) in their formularies, offering plan participants, such as Health Plans of the PBM, the opportunity to access this treatment option.

According to Francine Galante, Vice President of Market Access at Celltrion USA, this agreement is a significant step towards providing treatment options for millions of patients suffering from chronic diseases. Celltrion USA remains committed to collaborating with healthcare providers, patients, and physicians to develop innovative therapies that address the needs of individuals living with chronic debilitating pain.

It is worth noting that ZYMFENTRA, Celltrion's FDA-approved subcutaneous infliximab, is now commercially available in the United ...
... States. The company is actively engaging with national and regional health plans, as well as Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs), to highlight the value of their FDA-approved therapies, including ZYMFENTRA, for patients with autoimmune diseases and to ensure comprehensive coverage.

More Information : https://www.techdogs.com/tech-news/pr-newswire/celltrion-usa-signs-agreement-with-express-scripts-for-its-therapy-for-autoimmune-diseases-including-the-first-fda-approved-subcutaneous-infliximab-zymfentra